Microbio Co

Microbio Co Equity

The The Equity of Microbio Co (4128.TWO) as of Nov 2, 2026 is 8.91 B TWD. In the previous year, The Equity was 10.31 B TWD — a change of -13.51% (lower).

Equity

8.91 BTWD

YoY

-13.51%

Last updated:

In 2025, Microbio Co's equity was 8.91 B TWD, a -13.51% increase from the 10.31 B TWD equity in the previous year.

The Microbio Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
7.33 B TWD
Jan 1, 2019
6.71 B TWD
Jan 1, 2020
10.63 B TWD
Jan 1, 2021
11.89 B TWD
Jan 1, 2022
12.09 B TWD
Jan 1, 2023
11.81 B TWD
Jan 1, 2024
10.31 B TWD
Jan 1, 2025
8.91 B TWD
The Microbio Co Equity history
YEAREquityYoY
8.91 BTWD-13.51%
10.31 BTWD-12.75%
11.81 BTWD-2.33%
12.09 BTWD+1.67%
11.89 BTWD+11.91%
10.63 BTWD+58.40%
6.71 BTWD-8.47%
7.33 BTWD-5.10%
7.72 BTWD+6.80%
7.23 BTWD-5.41%
7.65 BTWD-1.53%
7.76 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Microbio Co Stock analysis

What does Microbio Co do? Microbio Co., Ltd. generates revenue through the sale of fermentation products like Tien Chun Bao (TCB) oral solutions, herbal products such as the LeeHerb series, and organic foods including vegetables, fruits, nuts, pastry, seasonings, and organic meals. The company also sells new medicines, including anticancer drugs, hepatitis treatments, allergy medications, and rheumatoid arthritis therapies. Domestic market sales form the primary distribution channel for all product lines. The firm targets consumers seeking natural health solutions through its Tien Chun Bao and LeeHerb product lines, while healthcare professionals and patients requiring specialized treatments purchase its new medicines. Organic food buyers include health-conscious individuals and households looking for sustainable dietary options. All products are sold within Taiwan's domestic market, with no international distribution mentioned. Microbio Co., Ltd. focuses on three core product segments: fermentation-based health solutions, herbal healthcare products, and organic food items. The anticancer and hepatitis medicine segments serve medical professionals and patients in Taiwan, while allergy and rheumatoid arthritis treatments target specific patient groups. The company's product portfolio is fully contained within Taiwan's domestic market, with no indication of international expansion. Microbio Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Microbio Co's Equity

Microbio Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Microbio Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Microbio Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Microbio Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Microbio Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Microbio Co stock

The Equity of Microbio Co is 8.91 B TWD in 2025.

The Equity of Microbio Co changed from 10.31 B TWD to 8.91 B TWD, representing a -13.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Microbio Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Microbio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Microbio Co

All Key Metrics — Microbio Co